Literature DB >> 11229728

Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy.

A M Campbell1, I H Bailey, M A Burton.   

Abstract

Radiation dose distributions arising from intrahepatic arterial infusion of 90Y microspheres have been investigated. Tissue samples from normal liver, the tumour periphery and tumour centre were taken from a patient following infusion of 3 GBq of 32 microm diameter resin microspheres labelled with 90Y as treatment for an 80 mm diameter metastatic liver tumour. The measured microsphere distributions in three dimensions were used to calculate radiation dose patterns. Although microspheres concentrated in the tumour periphery, heterogeneous doses were delivered to all tissues. Within the tumour periphery average doses ranged from 200 Gy to 600 Gy with minimum doses between 70 Gy and 190 Gy. The average and minimum doses for the tumour centre sample were 6.8 Gy and 3.7 Gy respectively. In the normal liver sample the average dose was 8.9 Gy with a minimum dose of 5 Gy. Less than 1% of the normal liver tissue volume received more than 30 Gy, the level above which complications have resulted for whole liver exposure using external beam radiotherapy. These calculations suggest that preferential deposition of microspheres in the well-vascularized periphery of large tumours will lead to a high proportion of the tumour volume receiving a therapeutic dose, with most of the normal liver tissue being spared substantial damage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229728     DOI: 10.1088/0031-9155/46/2/315

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  24 in total

1.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

Review 2.  SIRT of liver metastases: physiological and pathophysiological considerations.

Authors:  Christophe Van de Wiele; Alex Maes; Eddy Brugman; Yves D'Asseler; Bart De Spiegeleer; Gilles Mees; Karin Stellamans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-17       Impact factor: 9.236

Review 3.  Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer.

Authors:  Lourens Bester; Baerbel Meteling; David Boshell; Akshat Saxena; David L Morris
Journal:  Hepat Oncol       Date:  2014-03-20

Review 4.  SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers.

Authors:  Rita Golfieri
Journal:  Hepat Oncol       Date:  2014-09-09

5.  Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases.

Authors:  Terence C Chua; Lourens Bester; Akshat Saxena; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2010-09-22       Impact factor: 4.553

Review 6.  Liver metastases from colorectal cancer: radioembolization with systemic therapy.

Authors:  Nils H Nicolay; David P Berry; Ricky A Sharma
Journal:  Nat Rev Clin Oncol       Date:  2009-11-03       Impact factor: 66.675

7.  A review of 3D image-based dosimetry, technical considerations and emerging perspectives in 90Y microsphere therapy.

Authors:  Jim O' Doherty
Journal:  J Diagn Imaging Ther       Date:  2015-04-28

8.  Radioembolisation with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment.

Authors:  Marta Cremonesi; Mahila Ferrari; Mirco Bartolomei; Franco Orsi; Guido Bonomo; Demetrio Aricò; Andrew Mallia; Concetta De Cicco; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-10       Impact factor: 9.236

Review 9.  Optimizing Loco Regional Management of Oligometastatic Colorectal Cancer: Technical Aspects and Biomarkers, Two Sides of the Same Coin.

Authors:  Giovanni Mauri; Lorenzo Monfardini; Andrea Garnero; Maria Giulia Zampino; Franco Orsi; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Marco Busso; Carlo Gazzera; Paolo Fonio; Andrea Veltri; Marco Calandri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

10.  Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres.

Authors:  Elisa Melucci; Maurizio Cosimelli; Livio Carpanese; Giuseppe Pizzi; Francesco Izzo; Francesco Fiore; Rita Golfieri; Emanuela Giampalma; Isabella Sperduti; Cristiana Ercolani; Rosa Sciuto; Raffaello Mancini; Carlo Garufi; Maria Grazia Diodoro; Marcella Mottolese
Journal:  J Exp Clin Cancer Res       Date:  2013-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.